Ana Sánchez-Pitiot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana Sánchez-Pitiot has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Iñigo Santamaría
Laboratorio de Oncología Molecular, Hospital Universitario Central de Asturias & Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
8 shared publications - Aurora Astudillo
Hospital Universitario Central de Asturias
7 shared publications Milagros Balbín
Service of Molecular Oncology Hospital Central de Asturias Oviedo Spain
6 shared publications- Milagros Balbín
Laboratorio de Oncología Molecular, Hospital Universitario Central de Asturias & Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
6 shared publications - Xose S. Puente
Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain
5 shared publications - Milagros Balbín
Molecular Oncology Laboratory, Instituto Universitario de Oncologia del Principado de Asturias, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain
4 shared publications
Latest Publications
- Open Access
- 24 June 2024
- Published by Wiley in Clinical Genetics
- Vol. 106 (4) , 525-531
Featuring BRCA1 and BRCA2 germline mutational landscape from Asturias (North Spain)
The singular BRCA1/2 mutational landscape of Asturias is updated 10 years after the first study. We analyzed BRCA1 and BRCA2 pathogenic variants in 1653 index cases. In total, 238 families were identified to carry a pathogenic variant, 163 families in BRCA1 and 75 families in BRCA2. This yielded a prevalence rate of 14.4%. Seven recurrent variants were found accounting for 55% of the cases. Among them, three are widely distributed (BRCA1 c.211A>G, c.470_471del and c.3331_3334del) and four had been reported as novel in Asturias: two in BRCA1 (c.1674del and c.2901_2902dup) and two in BRCA2 (c.2095C>T and c.4040_4035delinsC). A common haplotype was established for all recurrent variants indicating a shared ancestral origin. Three splicing analyses are shown: BRCA1:c.5152+3A>C and BRCA1:c.5333‐3T>G that lead to skipping of exon 18, and 22 respectively, and BRCA1:c.5278‐1G>T giving rise to two transcripts, one lacking exon 21 (p.Ille1760Glyfs*60) and one lacking the first 8 nucleotides of exon 21 (p.Phe1761Asnfs*14), supporting pathogenicity for these variants.
- 24 June 2024
- Published by Wiley in Clinical Genetics
- Vol. 106 (4) , 525-531
Open AccessFeaturing BRCA1 and BRCA2 germline mutational landscape from Asturias (North Spain)
The singular BRCA1/2 mutational landscape of Asturias is updated 10 years after the first study. We analyzed BRCA1 and BRCA2 pathogenic variants in 1653 index cases. In total, 238 families were identified to carry a pathogenic variant, 163 families in BRCA1 and 75 families in BRCA2. This yielded a prevalence rate of 14.4%. Seven recurrent variants were found accounting for 55% of the cases. Among them, three are widely distributed (BRCA1 c.211A>G, c.470_471del and c.3331_3334del) and four had been reported as novel in Asturias: two in BRCA1 (c.1674del and c.2901_2902dup) and two in BRCA2 (c.2095C>T and c.4040_4035delinsC). A common haplotype was established for all recurrent variants indicating a shared ancestral origin. Three splicing analyses are shown: BRCA1:c.5152+3A>C and BRCA1:c.5333‐3T>G that lead to skipping of exon 18, and 22 respectively, and BRCA1:c.5278‐1G>T giving rise to two transcripts, one lacking exon 21 (p.Ille1760Glyfs*60) and one lacking the first 8 nucleotides of exon 21 (p.Phe1761Asnfs*14), supporting pathogenicity for these variants.
- Open Access
- 1 January 2023
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 13, e2023434
Fatal sclerosing mesenteritis: a 7-year-old male autopsy case report
Autops Case Rep, vol.13, e2023434, 2023
- 1 January 2023
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 13, e2023434
Open AccessFatal sclerosing mesenteritis: a 7-year-old male autopsy case report
Autops Case Rep, vol.13, e2023434, 2023
- Open Access
- 14 March 2022
- Published by Springer Nature in npj Genomic Medicine
- Vol. 7 (1) , 1-12
PanCancer analysis of somatic mutations in repetitive regions reveals recurrent mutations in snRNA U2
Current somatic mutation callers are biased against repetitive regions, preventing the identification of potential driver alterations in these loci. We developed a mutation caller for repetitive regions, and applied it to study repetitive non protein-coding genes in more than 2200 whole-genome cases. We identified a recurrent mutation at position c.28 in the gene encoding the snRNA U2. This mutation is present in B-cell derived tumors, as well as in prostate and pancreatic cancer, suggesting U2 c.28 constitutes a driver candidate associated with worse prognosis. We showed that the GRCh37 reference genome is incomplete, lacking the U2 cluster in chromosome 17, preventing the identification of mutations in this gene. Furthermore, the 5′-flanking region of WDR74, previously described as frequently mutated in cancer, constitutes a functional copy of U2. These data reinforce the relevance of non-coding mutations in cancer, and highlight current challenges of cancer genomic research in characterizing mutations affecting repetitive genes.
- 14 March 2022
- Published by Springer Nature in npj Genomic Medicine
- Vol. 7 (1) , 1-12
Open AccessPanCancer analysis of somatic mutations in repetitive regions reveals recurrent mutations in snRNA U2
Current somatic mutation callers are biased against repetitive regions, preventing the identification of potential driver alterations in these loci. We developed a mutation caller for repetitive regions, and applied it to study repetitive non protein-coding genes in more than 2200 whole-genome cases. We identified a recurrent mutation at position c.28 in the gene encoding the snRNA U2. This mutation is present in B-cell derived tumors, as well as in prostate and pancreatic cancer, suggesting U2 c.28 constitutes a driver candidate associated with worse prognosis. We showed that the GRCh37 reference genome is incomplete, lacking the U2 cluster in chromosome 17, preventing the identification of mutations in this gene. Furthermore, the 5′-flanking region of WDR74, previously described as frequently mutated in cancer, constitutes a functional copy of U2. These data reinforce the relevance of non-coding mutations in cancer, and highlight current challenges of cancer genomic research in characterizing mutations affecting repetitive genes.
- 14 December 2018
- Published by Wiley in Head & Neck
- Vol. 41 (1) , 79-91
Clinical significance and peculiarities of succinate dehydrogenase B and hypoxia inducible factor 1α expression in parasympathetic versus sympathetic paragangliomas
Background: Succinate dehydrogenase subunit B (SDHB) immunohistochemistry was considered a valuable tool to identify patients with inherited paraganglioma/pheochromocytoma (PGL/PCC). However, previous studies jointly analyzed 2 related but clinically distinct entities, parasympathetic head and neck paragangliomas (HNPGLs) and sympathetic PCCs/PGLs. Additionally, a role for hypoxia inducible factor‐1α (HIF‐1α) as a biomarker for succinate dehydrogenase (SDHx)‐mutated tumors has not been studied. Here, we evaluated the utility of SDHB/HIF‐1α proteins in HNPGLs and PCCs/PGLs as clinically useful biomarkers.Methods: The SDHB/succinate dehydrogenase subunit A (SDHA)/HIF‐1α immunohistochemistry analysis was performed in 158 genetically defined patients.Results: Similarly to PCCs/PGLs, SDHB immune‐negativity correlated with SDHx‐mutations in HNPGLs (P < .0001). The HIF‐1α stabilization was associated with SDHx‐mutations in HNPGLs (P = .020), not in PCCs/PGLs (P = .319). However, 25% of SDHx‐HNPGLs lacked HIF‐1α positive cells.Conclusion: As in PCCs/PGLs, SDHB immunohistochemistry in HNPGLs is a valuable method for identification of candidates for SDHx‐genetic testing. On the contrary, although SDHx mutations may favor HIF‐1α stabilization in HNPGLs, this is not a clinically useful biomarker.
- 14 December 2018
- Published by Wiley in Head & Neck
- Vol. 41 (1) , 79-91
Clinical significance and peculiarities of succinate dehydrogenase B and hypoxia inducible factor 1α expression in parasympathetic versus sympathetic paragangliomas
Background: Succinate dehydrogenase subunit B (SDHB) immunohistochemistry was considered a valuable tool to identify patients with inherited paraganglioma/pheochromocytoma (PGL/PCC). However, previous studies jointly analyzed 2 related but clinically distinct entities, parasympathetic head and neck paragangliomas (HNPGLs) and sympathetic PCCs/PGLs. Additionally, a role for hypoxia inducible factor‐1α (HIF‐1α) as a biomarker for succinate dehydrogenase (SDHx)‐mutated tumors has not been studied. Here, we evaluated the utility of SDHB/HIF‐1α proteins in HNPGLs and PCCs/PGLs as clinically useful biomarkers.Methods: The SDHB/succinate dehydrogenase subunit A (SDHA)/HIF‐1α immunohistochemistry analysis was performed in 158 genetically defined patients.Results: Similarly to PCCs/PGLs, SDHB immune‐negativity correlated with SDHx‐mutations in HNPGLs (P < .0001). The HIF‐1α stabilization was associated with SDHx‐mutations in HNPGLs (P = .020), not in PCCs/PGLs (P = .319). However, 25% of SDHx‐HNPGLs lacked HIF‐1α positive cells.Conclusion: As in PCCs/PGLs, SDHB immunohistochemistry in HNPGLs is a valuable method for identification of candidates for SDHx‐genetic testing. On the contrary, although SDHx mutations may favor HIF‐1α stabilization in HNPGLs, this is not a clinically useful biomarker.
- 14 March 2018
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 21 (4) , 747-754
TP53 p.R72P genotype is a marker of poor prognosis in lung cancer
BACKGROUND: Lung cancer is a leading cause of death worldwide, with poor survival rates despite diagnostic and therapeutic advances. Markers are needed in order to improve clinical patient management and survival. TP53 is frequently involved in lung
- 14 March 2018
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 21 (4) , 747-754
TP53 p.R72P genotype is a marker of poor prognosis in lung cancer
BACKGROUND: Lung cancer is a leading cause of death worldwide, with poor survival rates despite diagnostic and therapeutic advances. Markers are needed in order to improve clinical patient management and survival. TP53 is frequently involved in lung
- Open Access
- 21 September 2017
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 102 (12) , e510-e513
A t(1;9) translocation involving CSF3R as a novel mechanism in unclassifiable chronic myeloproliferative neoplasm
Atypical chronic myeloid leukemia (aCML), chronic neutrophilic leukemia (CNL), and unclassifiable chronic myeloproliferative neoplasm (MPN-U) constitute rare hematological neoplasms characterized by the abnormal expansion of granulocytes or neutrophils in bone marrow and peripheral blood in absence
- 21 September 2017
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 102 (12) , e510-e513
Open AccessA t(1;9) translocation involving CSF3R as a novel mechanism in unclassifiable chronic myeloproliferative neoplasm
Atypical chronic myeloid leukemia (aCML), chronic neutrophilic leukemia (CNL), and unclassifiable chronic myeloproliferative neoplasm (MPN-U) constitute rare hematological neoplasms characterized by the abnormal expansion of granulocytes or neutrophils in bone marrow and peripheral blood in absence
- Open Access
- 21 February 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-6
Identification of somatic and germ-line DICER1 mutations in pleuropulmonary blastoma, cystic nephroma and rhabdomyosarcoma tumors within a DICER1 syndrome pedigree
DICER1 syndrome is a pediatric cancer predisposition condition causing a variety of tumor types in children and young adults. In this report we studied a family with two relatives presenting a variety of neoplastic conditions at childhood. Germ-line mutation screening of the complete coding region of the DICER1 gene in genomic DNA from the proband was performed. The presence of somatic DICER1 mutation and further alterations in driver genes was investigated in genomic DNA obtained from available tumor samples. A nonsense germ-line mutation in DICER1 causing a truncated protein at the IIIb domain level was identified segregating within a family including two affected relatives who developed in one case cystic nephroma and pleuropulmonary blastoma, and rhabdomyosarcoma and multinodular goiter in the other. Additional in trans DICER1 missense somatic mutations in the IIIb DICER1 domain were found both in the cystic nephroma and in the rhabdomyosarcoma, suggesting that neoplasms in this family might arise from the unusual two-hit mechanism for DICER-derived tumorigenesis in which after the presence of a truncated constitutive protein, a neomorphic DICER1 activity is somatically adquired. Additional genetic alterations, such as TP53 mutations, were identified in the rhabdomyosarcoma. Besides DICER1 loss of standard activity, oncogenic cooperation of other genes, as mutated TP53, may involve developing higher grade tumors within this syndrome. Given the broad clinical spectrum that may arise, genetic counseling and close surveillance must be offered to all family members at risk of DICER1 syndrome.
- 21 February 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-6
Open AccessIdentification of somatic and germ-line DICER1 mutations in pleuropulmonary blastoma, cystic nephroma and rhabdomyosarcoma tumors within a DICER1 syndrome pedigree
DICER1 syndrome is a pediatric cancer predisposition condition causing a variety of tumor types in children and young adults. In this report we studied a family with two relatives presenting a variety of neoplastic conditions at childhood. Germ-line mutation screening of the complete coding region of the DICER1 gene in genomic DNA from the proband was performed. The presence of somatic DICER1 mutation and further alterations in driver genes was investigated in genomic DNA obtained from available tumor samples. A nonsense germ-line mutation in DICER1 causing a truncated protein at the IIIb domain level was identified segregating within a family including two affected relatives who developed in one case cystic nephroma and pleuropulmonary blastoma, and rhabdomyosarcoma and multinodular goiter in the other. Additional in trans DICER1 missense somatic mutations in the IIIb DICER1 domain were found both in the cystic nephroma and in the rhabdomyosarcoma, suggesting that neoplasms in this family might arise from the unusual two-hit mechanism for DICER-derived tumorigenesis in which after the presence of a truncated constitutive protein, a neomorphic DICER1 activity is somatically adquired. Additional genetic alterations, such as TP53 mutations, were identified in the rhabdomyosarcoma. Besides DICER1 loss of standard activity, oncogenic cooperation of other genes, as mutated TP53, may involve developing higher grade tumors within this syndrome. Given the broad clinical spectrum that may arise, genetic counseling and close surveillance must be offered to all family members at risk of DICER1 syndrome.
- Open Access
- 27 December 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (4) , 6700-6717
Role of VHL, HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate
Role of VHL , HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate
- 27 December 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (4) , 6700-6717
Open AccessRole of VHL, HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate
Role of VHL , HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate
- 6 October 2016
- Published by American Society of Hematology in Blood
- Vol. 128 (14) , 1894-1896
Transplacental transfer of essential thrombocythemia in monozygotic twins
- 6 October 2016
- Published by American Society of Hematology in Blood
- Vol. 128 (14) , 1894-1896
Transplacental transfer of essential thrombocythemia in monozygotic twins
- 1 October 2013
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 98 (10) , E1661-E1666
Identification of SomaticVHLGene Mutations in Sporadic Head and Neck Paragangliomas in Association With Activation of the HIF-1α/miR-210 Signaling Pathway
Context: Head and neck paragangliomas (HNPGLs) arise from parasympathetic paraganglias and 35% to 45% are hereditary caused by mutations in succinate dehydrogenase (SDH) genes. The connection between SDH and tumor development is unclear. The most accepted hypothesis proposes a central role for the pseudohypoxic (pHx) pathway activated by hypoxia-inducible factor (HIF). Paradoxically, we showed that activation of HIF in HNPGLs is restricted to a subset of HNPGLs lacking SDH mutations. These tumors overexpress HIF-1 alpha protein and target genes and the HIF-inducible microRNA miR-210 (pHx-HNPGLs). Objective: The present study aimed at unraveling the SDH-independent mechanisms involved in the activation of HIF in HNPGLs. Design: The VHL gene was analyzed in 53 tumors by gene sequencing, multiplex-ligation-dependent probe amplification, and quantitative PCR. The miR-210, HIF-1 alpha, and CA9 levels were used as markers of the pHx gene signature. Meta-analysis of the transcriptome of pHx-HNPGLs was performed using the Oncomine platform. Assays in cells lacking functional pVHL and HIF-1 alpha were performed to analyze the role of pVHL/HIF-1 alpha on miR-210 expression. Results: We identified, for the first time, somatic VHL mutations in HNPGLs. These were found in 2 of 4 pHx-HNPGLs with concomitant loss of heterozygosity in one of them; but not in non-pHx-HNPGLs. Meta-analysis of the transcriptome of pHx-HNPGLs revealed that these tumors are highly related to clear cell renal cell carcinoma. Cell-based assays showed that loss of pVHL lead to up-regulation of miR-210 mainly via HIF-1 alpha activation. Conclusions: VHL, involved in tumorigenesis of PGLs and clear cell renal cell carcinomas, may be an important player in the pathogenesis of sporadic HNPGLs via activation of an HIF-1 alpha/miR-210 pHx pathway.
- 1 October 2013
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 98 (10) , E1661-E1666
Identification of SomaticVHLGene Mutations in Sporadic Head and Neck Paragangliomas in Association With Activation of the HIF-1α/miR-210 Signaling Pathway
Context: Head and neck paragangliomas (HNPGLs) arise from parasympathetic paraganglias and 35% to 45% are hereditary caused by mutations in succinate dehydrogenase (SDH) genes. The connection between SDH and tumor development is unclear. The most accepted hypothesis proposes a central role for the pseudohypoxic (pHx) pathway activated by hypoxia-inducible factor (HIF). Paradoxically, we showed that activation of HIF in HNPGLs is restricted to a subset of HNPGLs lacking SDH mutations. These tumors overexpress HIF-1 alpha protein and target genes and the HIF-inducible microRNA miR-210 (pHx-HNPGLs). Objective: The present study aimed at unraveling the SDH-independent mechanisms involved in the activation of HIF in HNPGLs. Design: The VHL gene was analyzed in 53 tumors by gene sequencing, multiplex-ligation-dependent probe amplification, and quantitative PCR. The miR-210, HIF-1 alpha, and CA9 levels were used as markers of the pHx gene signature. Meta-analysis of the transcriptome of pHx-HNPGLs was performed using the Oncomine platform. Assays in cells lacking functional pVHL and HIF-1 alpha were performed to analyze the role of pVHL/HIF-1 alpha on miR-210 expression. Results: We identified, for the first time, somatic VHL mutations in HNPGLs. These were found in 2 of 4 pHx-HNPGLs with concomitant loss of heterozygosity in one of them; but not in non-pHx-HNPGLs. Meta-analysis of the transcriptome of pHx-HNPGLs revealed that these tumors are highly related to clear cell renal cell carcinoma. Cell-based assays showed that loss of pVHL lead to up-regulation of miR-210 mainly via HIF-1 alpha activation. Conclusions: VHL, involved in tumorigenesis of PGLs and clear cell renal cell carcinomas, may be an important player in the pathogenesis of sporadic HNPGLs via activation of an HIF-1 alpha/miR-210 pHx pathway.